The potential of using reprogramming to generate healthy HSCs from an AML patient has yet to be explored and it remains unclear whether the generation of AML-patient HSCs is even possible or capable of bestowing surrogate properties such as SRC capacity. The gene discussed is SRC; the disease is acute myeloid leukemia.